Mnemo Therapeutics
Transformational immunotherapies development
- 21-100 employees
- B2B
- Deep Tech
- Biology
- MedTech
- Auteuil, Paris, France
Jump to section
Company mission
To develop groundbreaking immunotherapies for people with cancer.
Our take
Mnemo Therapeutics is a biotechnology company focused on discovering and developing immune-based therapies, such as powerful cell therapies that create accessible cures for solid tumours and blood cancers.
The company’s drug discovery engine – called EnfiniT – leverages a new class of antigens with greater tumour specificity and its suite of tools further improves T-cell memory, persistence, and sensitivity. Such research and therapy development is critical to finding solutions that improve the body’s ability to fight and overcome cancer.
The company has published two studies - developed at Institut Curie – in the journal of Science Immunology that further validate its antigen discovery platform. Due to its applicability to provide therapy solutions to a range of oncology indications, Mnemo Therapies is well set to play an integral role in pioneering the future of immunotherapy development.
Steph
Company Specialist at Welcome to the Jungle
Funding (1 round)
Jun 2021
$78.3m
SERIES A
Total funding: $78.3m
Leadership
Alain Maiore
(COO)Served as the company's CEO from Jan 2019 - Apr 2022 before transitioning into their current role. Former CEO of Minka-Tx and Kesios Therapeutics. Founder & former Managing Partner of Kurma Partners.